5 Papers
12 Citations
Xing Wan is an academic researcher from Huazhong University of Science and Technology. The author has contributed to research in topics: Leber's hereditary optic neuropathy & Optic neuropathy. The author has an hindex of 4, co-authored 5 publications.
Chat about Author
Papers
Efficacy and Safety of rAAV2-ND4 Treatment for Leber’s Hereditary Optic Neuropathy
Xing Wan,Han Pei,Min-jian Zhao,Shuo Yang,Weikun Hu,Heng He,Si-qi Ma,Ge Zhang,Xiao-yan Dong,Chen Chen,Dao Wen Wang,Bin Li +11 more
TL;DR: Findings support the feasible use of gene therapy for LHON by evaluating the efficacy and safety of a recombinant adeno-associated virus 2 carrying ND4 (rAAV2-ND4) in LHON patients carrying the G11778A mutation.
Long-term outcomes of gene therapy for the treatment of Leber's hereditary optic neuropathy.
Shuo Yang,Si-qi Ma,Xing Wan,Heng He,Han Pei,Min-jian Zhao,Chen Chen,Dao Wen Wang,Xiao-yan Dong,Jiajia Yuan,Bin Li +10 more
TL;DR: The results support the use of intravitreal rAAV2-ND4 as an aggressive maneuver in the clinical trial and further study in additional patients and in these 9 subjects is needed to better understand the effects of rAAv2- ND4 gene therapy on LHON and to increase the applications of this technique.
118
•Journal Article
Construction and detection of a novel type of recombinant human rAAV2/2-ND4.
TL;DR: A new type of rAAV2/2-ND4 was successfully constructed and may have potential in gene therapy for LHON, and specifically amplified the target gene band of ND4.
14
Multilocus Mitochondrial Mutations Do Not Directly Affect the Efficacy of Gene Therapy for Leber Hereditary Optic Neuropathy.
TL;DR: Investigating whether multilocus mitochondrial mutations directly influence the efficacy of gene therapy for Leber hereditary optic neuropathy found detection of the 3 primary mitochondrial mutations causing LHON is sufficient for screening before gene therapy; sequencing of the entire mitochondrial genome is unnecessary before treatment.
5
Seven-Year Follow-up of Gene Therapy for Leber's Hereditary Optic Neuropathy.
Jiajia Yuan,Yong Zhang,Hongli Liu,Dan Wang,Yang‐yang Du,Zhen Tian,Xin Li,Shuo Yang,Han Pei,Xing Wan,Su Xiao,Lin Song,Xiao Xiao,Jian Sun,Zhitao Wang,Bin Li,Bin Li +16 more
TL;DR: The rAAV2-ND4 gene therapy that targets mt11778G>A was delivered to nine patients with Leber’s hereditary optic neuropathy and continues to be safe and potentially effective at long-term follow-up.